E
EnzymeRx
enzymerx.com - Deze website is te koop! - de beste bron van informatie over enzymerx.
About EnzymeRx
EnzymeRx, LLC operated as a clinical-stage biopharmaceutical firm, established in 2008 with its headquarters in Paramus, New Jersey. The company focused its efforts on developing therapeutic solutions for conditions stemming from hyperuricemia, specifically targeting resistant and refractory gout.
The company's primary undertaking was the development of uricase-PEG 20, a pegylated variant of the uricase enzyme. This product, obtained from *Candida utilis*, was engineered to have a prolonged half-life and diminished immunogenicity. The therapeutic was aimed at patients who were unresponsive to or could not tolerate existing treatments for severe gout. In May 2008, EnzymeRx secured $14 million in a Series A funding round from investors including Pequot Capital Management and FirstMark Capital. This capital injection facilitated the acquisition of worldwide rights (excluding Taiwan) to uricase-PEG 20 from Polaris Pharmaceuticals, which had already advanced the drug through a Phase I clinical trial.
The business strategy centered on advancing uricase-PEG 20 through further clinical trials, with plans for a multi-dose Phase II study in refractory gout patients. The company's President and CEO was Tony Fiorino, MD, PhD. In a strategic move to focus on its core oncology programs, Polaris Pharmaceuticals divested the asset while retaining an equity stake in EnzymeRx. The company's journey as an independent entity concluded on November 29, 2010, when it was acquired by the Chinese biopharmaceutical company 3Sbio for $6.25 million.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | May 2008 | $14M | $56M | Undisclosed | — |
Growth signals
Latest recorded traffic for EnzymeRx is 110 monthly website visits. EnzymeRx's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
EnzymeRx in the Paramus ecosystem
The EnzymeRx office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about EnzymeRx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EnzymeRx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







